PD-L1 Biomarker May Advance Immunotherapy Treatment For Early Stage Breast Cancer

PD-L1 Biomarker May Advance Immunotherapy Treatment For Early Stage Breast Cancer
PD-L1 breast cancer biomarkerA newly developed molecular assay, PD-L1, was used to detect the levels of an important biomarker for immunotherapy in treating early stage breast cancers. Because the programmed death ligand/receptor1 (PD-1/PD-L1) axis plays a major role in the suppression of the immune system, allowing tumors to evade immune detection, blocking these transmembrane proteins has emerged as a promising, new therapy for different types of cancers. The levels of PD-L1 protein expression in a tumor can predict the response to drugs targeting this pathway. However, until now, the tools to measure PD-L1 were limited, with no standardized immunohistochemical methods and a recurrent inconstancy of antibodies. With the aim to correlate PD-L1 mRNA expression with clinical variables in primary breast carcinomas, a team of researchers from Yale School of Medicine, New Haven, Connecticut, developed a fluorescent RNAscope paired-primer assay to quantify PD-L1 mRNA levels in 636 stage I-III breast carcinomas on two sets of tissue microarrays. The researchers verified that PD-L1 mRNA was identified in roughly 60% of all breast tumors analyzed, with higher PD-L1 mRNA expression significantly correlating with increased numbers of tumor infiltrating lymphocytes (TILs), a phenomenon associated with an estrogen receptor-negative status of breast tumors. Moreover, the data revealed that expression of PD-L1 mRNA was associated
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.